Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells

Journal of Oncology

Volumn , Issue , 2013, Pages

  Nejatollahi, Foroogh ^a,b   Abdi, Soghra ^a   Asgharpour, Mahdi ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893829723     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/839831     Document Type: Article

References (41)

1. Reiter R. E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., Wahl M., Nisitani S., Yamashiro J., Le Beau M. M., Loda M., Witte O. N., Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 1998 95 4 1735 1 (Pubitemid 28103463)
2. Dannull J., Diener P.-A., Prikler L., Furstenberger G., Cerny T., Schmid U., Ackermann D. K., Groettrup M., Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Research 2000 60 19 5522 5528 2-s2.0-0034306972
3. Gu Z., Thomas G., Yamashiro J., Shintaku I. P., Dorey F., Raitano A., Witte O. N., Said J. W., Loda M., Reiter R. E., Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000 19 10 1288 1296 2-s2.0-0034594917 (Pubitemid 30160621)
4. Amara N., Palapattu G. S., Schrage M., Gu Z., Thomas G. V., Dorey F., Said J., Reiter R. E., Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Research 2001 61 12 4660 4665 2-s2.0-0035875053 (Pubitemid 32691871)
5. Argani P., Rosty C., Reiter R. E., Wilentz R. E., Murugesan S. R., Leach S. D., Ryu B., Skinner H. G., Goggins M., Jaffee E. M., Yeo C. J., Cameron J. L., Kern S. E., Hruban R. H., Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Research 2001 61 11 4320 4324 2-s2.0-0035360275 (Pubitemid 32685751)
6. Grubbs E. G., Abdel-Wahab Z., Tyler D. S., Pruitt S. K., Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Annals of Surgical Oncology 2006 13 12 1645 1654 2-s2.0-33845677702 10.1245/s10434-006-9029-5 (Pubitemid 44951473)
7. Han K.-R., Seligson D. B., Liu X., Horvath S., Shintaku P. I., Thomas G. V., Said J. W., Reiter R. E., Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. Journal of Urology 2004 171 3 1117 1121 2-s2.0-1542267902 10.1097/01.ju.0000109982.60619.93 (Pubitemid 38327539)
8. Zhigang Z., Wenlu S., External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer. Prostate 2007 67 6 653 660 2-s2.0-34247594186 10.1002/pros.20536 (Pubitemid 46685286)
9. Zhigang Z., Wenlu S., Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005 65 4 299 305 2-s2.0-28744447319 10.1002/pros.20290 (Pubitemid 41759961)
10. Joung J. Y., Yang S. O., Jeong I. G., Han K. S., Seo H. K., Chung J., Park W. S., Lee K. H., Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer. International Journal of Urology 2007 14 7 635 643 2-s2.0-34447538484 10.1111/j.1442-2042.2007.01787.x (Pubitemid 47084106)
11. Moore M. L., Teitell M. A., Kim Y., Watabe T., Reiter R. E., Witte O. N., Dubey P., Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 2008 68 2 139 151 2-s2.0-38749113371 10.1002/pros.20686 (Pubitemid 351186226)
12. Saeki N., Gu J., Yoshida T., Wu X., Prostate stem cell antigen: a Jekyll and Hyde molecule? Clinical Cancer Research 2010 16 14 3533 3538 2-s2.0-77954748206 10.1158/1078-0432.CCR-09-3169
13. Deonarain M. P., Kousparou C. A., Epenetos A. A., Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 2009 1 12 25
14. Wente M. N., Jain A., Kono E., Berberat P. O., Giese T., Reber H. A., Friess H., Büchler M. W., Reiter R. E., Hines O. J., Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005 31 2 119 125 2-s2.0-23044451727 10.1097/01.mpa.0000173459.81193.4d (Pubitemid 41077139)
15. Ross S., Spencer S. D., Holcomb I., Tan C., Hongo J., Devaux B., Rangell L., Keller G. A., Schow P., Steeves R. M., Lutz R. J., Frantz G., Hillan K., Peale F., Tobin P., Eberhard D., Rubin M. A., Lasky L. A., Koeppen H., Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Research 2002 62 9 2546 2553 2-s2.0-0036569591 (Pubitemid 34462733)
16. Holliger P., Hudson P. J., Engineered antibody fragments and the rise of single domains. Nature Biotechnology 2005 23 9 1126 1136 2-s2.0-27144432842 10.1038/nbt1142 (Pubitemid 41486394)
17. Chester K., Pedley B., Tolner B., Violet J., Mayer A., Sharma S., Boxer G., Green A., Nagl S., Begent R., Engineering antibodies for clinical applications in cancer. Tumor Biology 2004 25 1-2 91 98 2-s2.0-3042545775 10.1159/000077727 (Pubitemid 38822775)
18. Emanuel P. A., Dang J., Gebhardt J. S., Aldrich J., Garber E. A. E., Kulaga H., Stopa P., Valdes J. J., Dion-Schultz A., Recombinant antibodies: a new reagent for biological agent detection. Biosensors and Bioelectronics 2000 14 10-11 751 759 2-s2.0-0033967387 10.1016/S0956-5663(99)00058-5 (Pubitemid 30055355)
19. Batra S. K., Jain M., Wittel U. A., Chauhan S. C., Colcher D., Pharmacokinetics and biodistribution of genetically engineered antibodies. Current Opinion in Biotechnology 2002 13 6 603 608 2-s2.0-0036898144 10.1016/S0958-1669(02)00352-X (Pubitemid 35448063)
20. Weisser N. E., Hall J. C., Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnology Advances 2009 27 4 502 520 2-s2.0-65549131364 10.1016/j.biotechadv.2009.04.004
21. Yokota T., Milenic D. E., Whitlow M., Schlom J., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Research 1992 52 12 3402 3408 2-s2.0-0026684815
22. Huston J. S., McCartney J., Tai M. S., Mottola-Hartshorn C., Jin D., Warren F., Keck P., Oppermann H., Medical applications of single-chain antibodies. International Reviews of Immunology 1993 10 2-3 195 217 2-s2.0-0027420237
23. Leong S. S. J., Chen W. N., Preparing recombinant single chain antibodies. Chemical Engineering Science 2008 63 6 1401 1414 2-s2.0-38949210239 10.1016/j.ces.2007.11.022
24. Hagemeyer C. E., von Zur Muhlen C., von Elverfeldt D., Peter K., Single-chain antibodies as diagnostic tools and therapeutic agents. Thrombosis and Haemostasis 2009 101 6 1012 1019 2-s2.0-67049155341 10.1160/TH08-12-0816
25. Nejatollahi F., Hodgetts S. J., Vallely P. J., Burnie J. P., Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunology and Medical Microbiology 2002 34 3 237 244 2-s2.0-0037111918 10.1016/S0928-8244(02)00400-5 (Pubitemid 35335525)
26. Nejatollahi F., Malek-Hosseini Z., Mehrabani D., Development of single chain antibodies to P185 tumor antigen. Iranian Red Crescent Medical Journal 2008 10 4 298 302 2-s2.0-66149152263
27. Ahmad S., Sweeney P., Sullivan G. C., Tangney M., DNA vaccination for prostate cancer from preclinical to clinical trials-where we stand? Genetic Vaccines and Therapy 2012 10, article 9 10.1186/1479-0556-10-9
28. Karan D., Dubey S., van Veldhuizen P., Holzbeierlein J. M., Tawfik O., Thrasher J. B., Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy 2011 3 6 735 746 2-s2.0-79959193683 10.2217/imt.11.59
29. Olafsen T., Gu Z., Sherman M. A., Leyton J. V., Witkosky M. E., Shively J. E., Raubitschek A. A., Morrison S. L., Wu A. M., Reiter R. E., Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. Journal of Immunotherapy 2007 30 4 396 405 2-s2.0-34247645942 10.1097/CJI.0b013e318031b53b (Pubitemid 46684429)
30. Leyton J. V., Olafsen T., Sherman M. A., Bauer K. B., Aghajanian P., Reiter R. E., Wu A. M., Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Engineering, Design and Selection 2009 22 3 209 216 2-s2.0-60749135609 10.1093/protein/gzn055
31. Leyton J. V., Olafsen T., Lepin E. J., Hahm S., Bauer K. B., Reiter R. E., Wu A. M., Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clinical Cancer Research 2008 14 22 7488 7496 2-s2.0-58149343901 10.1158/1078-0432.CCR-07-5093
32. Gu Z., Yamashiro J., Kono E., Reiter R. E., Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Research 2005 65 20 9495 9500 2-s2.0-27144471037 10.1158/0008-5472.CAN-05-2086 (Pubitemid 41508019)
33. Saffran D. C., Raitano A. B., Hubert R. S., Witte O. N., Reiter R. E., Jakobovits A., Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America 2001 98 5 2658 2663 2-s2.0-0035956985 10.1073/pnas.051624698 (Pubitemid 32209538)
34. Reiter R., Witte O. N., Antibody against prostate stem cell antigen (PSCA). Patent no: EP 1514876 A2, 2005
35. Reiter R., Witte O. N., Saffran D. C., Jakobovits A., Anti-PSCA antibodies. Patent no: US 6790939 B2, 2004
36. Matsueda S., Yao A., Ishihara Y., Ogata R., Noguchi M., Itoh K., Harada M., A prostate stem cell antigen-derived peptide immunogenic in HLA-A24-prostate cancer patients. Prostate 2004 60 3 205 213 2-s2.0-3242816285 10.1002/pros.20038 (Pubitemid 38971832)
37. Antonarakis E. S., Carducci M. A., Targeting angiogenesis for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets 2012 16 4 365 376 2-s2.0-84859569827 10.1517/14728222.2012.668887
38. Lian J., Wu X., He F., Karnak D., Tang W., Meng Y., Xiang D., Ji M., Lawrence T. S., Xu L., A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death and Differentiation 2011 18 1 60 71 2-s2.0-78650170269 10.1038/cdd.2010.74
39. Albrecht H., Denardo G. L., Denardo S. J., Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 51 4 304 313 2-s2.0-37249071981 (Pubitemid 350267701)
40. Parker S. A., Diaz I. L., Anderson K. A., Batt C. A., Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591. Protein Expression and Purification 2013 89 2 136 145 10.1016/j.pep.2013.02.016
41. Morgenroth A., Cartellieri M., Schmitz M., Günes S., Weigle B., Bachmann M., Abken H., Rieber E. P., Temme A., Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007 67 10 1121 1131 2-s2.0-34250839415 10.1002/pros.20608 (Pubitemid 46983341)